The goal of personalized medicine (PM) is to tailor medical treatments and services to the biological makeup of individual patients. This project provides a way to maximize investments made in PM technology to secure patient benefits, lower health care costs, and waste fewer resources. It does so by bridging informational gaps between PM researchers, developers, safety regulators, health system payers, and patients who require new and innovative treatments. The team will work with developers of treatments and with industry representatives to develop an evidence base and evaluation toolkit (economic, regulatory, legal, commercial, and social values-based) to increase transparency and understanding among the main stakeholders. Outcomes of this project will assist the PM industry by reducing uncertainty for potential developers and benefit the health care system by encouraging investment in the types of PM needed. Ultimately, this will enhance the adoption of high value PM treatments and services in Canada and allow the Canadian public to receive the PM interventions that will most increase their health, faster, and at a lower cost. The ultimate goal of this project is to develop processes and analytical tools to support public and private sector PM stakeholders to realize the potential of PM in Canada.
ClosedHealth
The Canadian COVID Genomics Network
FunderThe Canadian COVID Genomics Network - CanCOGeN
CompetitionThe Canadian COVID Genomics Network - CanCOGeN
Project Lead(s)/Co-Lead(s)Matthew Croxen (Alberta Precision Laboratories)